Novartis to highlight key data from extensive oncology portfolio at SABCS and...
Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating...
View ArticleTacrolimus plus sirolimus not better than standard regimen in preventing GVHD
An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the...
View ArticleDelaware District Court rules in favor of Pfizer in RAPAMUNE patent case
Pfizer Inc. said today that the United States District Court for the District of Delaware ruled that Pfizer's patent covering a method for using sirolimus, the active ingredient in RAPAMUNE®, for the...
View ArticleFDA accepts Merck's NDA for NOXAFIL tablets
Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL...
View ArticleSirolimus effective in treating children with Pretzel syndrome, new study...
With a better understanding of underlying mechanisms that cause a rare neurodevelopmental disorder in the Old Order Mennonite population, referred to as Pretzel syndrome, a new study reports that five...
View ArticleDrug alerts have variable impact on prescribing habits
Direct communication with healthcare professionals, in the form of so-called “Dear doctor” letters, can be effective in reducing inappropriate and unsafe use of medicines, Dutch scientists believe.
View ArticleTargeted therapy prevents rare neurodevelopmental disorder seizures
Rapamycin treatment reduces seizure frequency and improves receptive language in patients with polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome, or Pretzel syndrome, a study finds.
View ArticleElixir Medical receives FDA approval to initiate patient enrollment in...
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it has received approval from the Food and Drug...
View ArticleDESolve bioresorbable coronary scaffold system safe and effective, shows low...
The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the...
View ArticleOrbusNeich introduces COMBO Dual Therapy Stent
OrbusNeich today launched the world's first dual therapy stent – the COMBO Dual Therapy Stent – to address the challenges of delayed healing of the coronary artery associated with monotherapy drug...
View ArticleFDA approves Astellas' ASTAGRAF XL for prophylaxis of organ rejection in...
Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the U.S. Food and Drug Administration has approved ASTAGRAF XLTM (tacrolimus extended-release...
View ArticleResults announced for Phase 3B/4 study of RAPAMUNE in kidney transplant patients
Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to...
View ArticleSvelte completes enrollment in drug-eluting coronary stent Integrated...
Svelte Medical Systems today announced enrollment of the final patient in the DIRECT II (Direct Implantation of Rapamycin-Eluting stents with bioabsorbable drug Carrier Technology) clinical study....
View ArticleFDA accepts Merck's NOXAFIL IV solution NDA for priority review
Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational intravenous solution formulation of the company's antifungal agent,...
View ArticleFDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection
Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration has approved OLYSIO (simeprevir), an NS3/4A protease inhibitor, for the treatment of...
View ArticleMerck announces approval of NOXAFIL delayed-release tablets by FDA
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets.
View ArticleNovartis to present updates on broad cancer portfolio at ASH and SABCS...
Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer...
View ArticleMerck's NOXAFIL injection gets FDA approval for intravenous use
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of...
View ArticleAB Sciex launches immunosuppressants kit to improve health care
Every organ transplant patient in the world faces the potential danger of his/her body rejecting a new organ, such as a heart, kidney or liver. Immunosuppressant drugs are required to help prevent...
View ArticleResearch findings suggest new strategy in fight against HIV infection
New research suggests that drugs commonly used to prevent organ rejection after transplantation may also be helpful for combating HIV. The findings, which are published in the American Journal of...
View Article